Cardiovascular comorbidities were equally prevalent in full-dose and reduced-dose groups, suggesting well-controlled cardiovascular disease need not contraindicate standard dosing.

Outcomes remained poor overall, underscoring the need for clinical trials and novel therapies in this setting.

Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...

Learn how age, TP53 risk, and lifestyle shape choosing fixed-duration vs continuous CLL therapy, with shared decision tips from Dr Lamanna. While results from the CLL17 trial (NCT04608318) suggest ...

Results from the phase 3 CLL17 trial (NCT04608318) are helping clarify the ongoing debate over continuous vs fixed-duration ...

Disease characteristics, age, and geography are among the main factors that shape first-line treatment patterns in patients ...

Suchitra Sundaram, MD, shares that ASH 2025 presented major advances in chronic lymphocytic leukemia (CLL) across both time‑limited and continuous treatment strategies, and emphasized the growing role ...

Aging and CLL amplify fatigue, anemia, and infection risks, impacting physical activity and recovery. Tailored strategies, such as anti-inflammatory diets and strength training, can enhance resilience ...